0000771856FALSE00007718562024-10-152024-10-15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): October 14, 2024
 
CHAMPIONS ONCOLOGY, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware001-1150452-1401755
(State or Other Jurisdiction(Commission File Number)(IRS Employer
of Incorporation) Identification No.)
 
1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code: (201) 808-8400
 
Not applicable
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


 

INFORMATION TO BE INCLUDED IN THE REPORT
 
Item 5.07.Submission of Matters to a Vote of Security Holders.
 
On October 14, 2024, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:
 
1. Election of Directors. The seven director nominees named in the Company's 2024 proxy statement were elected to serve for a one-year term expiring at the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes:
 
Director NomineeVotes ForVotes WithheldBroker Non-Vote
Ronnie Morris, M.D.8,483,091685,123697,813
Joel Ackerman7,973,3091,194,905697,813
David Sidransky, M.D.7,997,9921,170,222697,813
Daniel Mendelson7,769,7991,398,415697,813
Scott R. Tobin9,167,706508697,813
Philip Breitfeld, MD.9,167,215999697,813
Robert Brainin7,888,2991,279,915697,813
 
2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2025, was ratified as follows:
 
Votes ForVotes AgainstAbstain
9,865,571256200
 
3. Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2024 proxy statement, was approved by the following votes:
 
Votes ForVotes AgainstAbstainBroker Non-Vote
9,162,2872,0273,900697,813

 

 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  CHAMPIONS ONCOLOGY, INC.
  (Registrant)
    
Date: October 15, 2024 By:/s/ David Miller
   David Miller
   Chief Financial Officer


v3.24.3
Cover Page
Oct. 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 14, 2024
Entity Registrant Name CHAMPIONS ONCOLOGY, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-11504
Entity Tax Identification Number 52-1401755
Entity Address, Address Line One 1 University Plaza, Suite 307
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 808-8400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Trading Symbol CSBR
Security Exchange Name NASDAQ
Title of 12(b) Security Common Stock, par value $0.001 per share
Entity Emerging Growth Company false
Entity Central Index Key 0000771856
Amendment Flag false
Champions Oncology (NASDAQ:CSBR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Champions Oncology Charts.
Champions Oncology (NASDAQ:CSBR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Champions Oncology Charts.